NCT03852524View on ClinicalTrials.gov

Subcutaneous Methylnaltrexone Versus Placebo for Postoperative Ileus Prevention

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

February 21, 2019

Primary Completion Date

April 4, 2021

Study Completion Date

May 12, 2021

Conditions
Postoperative Ileus
Interventions
DRUG

Methylnaltrexone

Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving methylnaltrexone (study drug) will receive a subcutaneous dose pre-surgery and daily for three days following surgery.

OTHER

Placebo

Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving placebo will receive a subcutaneous dose pre-surgery and daily for three days following surgery.

Trial Locations (1)

43210

Ohio State University, Columbus

All Listed Sponsors
lead

Ohio State University

OTHER

NCT03852524 - Subcutaneous Methylnaltrexone Versus Placebo for Postoperative Ileus Prevention | Biotech Hunter | Biotech Hunter